David Warshawsky, PhD
Founder, CEO, Chairman of the Board of Directors
David is an entrepreneur with more than 20 years of international experience in research, product development, management & business development in life sciences. David strongly believes in deploying multidimensional approaches to tackle big problems, and in utilizing data mining and bioinformatics, molecular biology and innovative drug discovery and clinical development approaches.
David was founder & CEO of LifeMap Sciences, Inc.; founder & CEO of XenneX, Inc.; and founder & CEO of Avraham Pharmaceuticals, Ltd.; VP, Theranica, and founder of Varinel, Inc.; VP, Business Development at Paramount Biosciences; and Director of Business Development World Wide at Compugen Inc. From 1996-1999 he was a research fellow at Harvard and Harvard Medical School. He earned his Ph.D. in Molecular Biology in 1995 from the University of Illinois at Chicago and B.Sc. in Biology from Tel Aviv University in 1991.
Rick Lampe, MSc
Co-Founder, Head of Product Development & Regulatory, Director
Rick brings a broad understanding of pharmaceutical industry based upon 30 years of experience in research and development functions. Rick brings a proven ability to resolve issues, lead teams and deliver outcomes in compliance with government and industry regulations.
Rick's experience includes a balanced portfolio of critical pharmaceutical development skills and experiences developed within multiple environments, including Avraham Pharmaceuticals, Ltd., YM Biosciences, Inc., Eximias Pharmaceuticals, Corp., and New River Pharmaceuticals, Inc., Fifteen years in various research, regulatory and project management positions at AstraZeneca Pharmaceuticals, and 8 years as staff scientist at E.I. Du Pont de Nemours & Co. Rick earned his M.S. in Biochemistry, University of Kansas, Lawrence, KS, 1981 and his B.Sc. in Neuropsychology, University of Virginia, Charlottesville, VA, 1975.
Robert E. Hurst, PhD
Co-Founder, Chief Scientific Officer, Director
Bob brings broad experience in novel therapeutic approaches to prevention and treatment of metastasis, biomarkers for diagnosis and prognosis of malignancy and the carcinogenic process. Bob is Professor Emeritus, Department of Urology, University of Oklahoma Health Sciences Center. He was also a founder of DormaTarg.
Bob has published over 150 peer reviewed papers and is listed as an inventor on 11 patents to date. In 2009 he was named "Innovator of the Year" by the "Oklahoma Journal Record", the State's business newspaper. Bob is a Fellow of the American Association for the Advancement of Science. Bob earned his Bachelor's of Science from Auburn University and his Ph.D. in biochemistry from Florida State University.
Raphael Nir, PhD
Co-Founder, Head of Preclinical Development
Raphael is a scientist, entrepreneur and angel investor with 27 years of biotechnology experience spanning preclinical research, drug discovery, cell-based assays, process development and recombinant cytokines production. He is founder and owner of SBH Sciences, which he built from the ground up to become a leading supplier of recombinant cytokines and a preferred discovery research organization that has assisted more than 180 biotechnology companies since 1997.
Raphael also co-founded the biotechnology companies Karyopharm Therapeutics (NASDAQ: KPTI), Galectin Sciences and Alma Bio Therapeutics, is co-founder of SBH Diagnostics, and co-founder and partner at Sky Ventures, Woodland Biosciences and ABI-LAB.
Raphael earned his Ph.D. in biotechnology his M.S. in biochemistry, and his B.S. in chemistry from Tel-Aviv University and his M.S. in engineering management from New Jersey Institute of Technology. He was a postdoctoral researcher at Schering Plough Research Institute where he later became a Senior Scientist/Associate Principal Scientist and developed innovative cell culture processes and solutions related to biological production.
Chand Khanna, DVM, PhD, DACVIM (Onc) Director
Dr. Khanna is currently the Chief Science Officer of Ethos Veterinary Health and President of the non-profit incubator of scientific innovation, Ethos Discovery (501c.3.). In these roles Dr. Khanna seeks to improve outcomes for human and pet patients with complex medical problems through the development of novel therapeutics and diagnostics.
Dr. Khanna was the longtime Head of the NCI Pediatric Oncology Branch’s Tumor and Metastasis Biology Section, and the Founding Director of the Center for Cancer Research, Comparative Oncology Program. His research interests and responsibilities focused on the problem of cancer metastasis and the discovery of new options to treat patients with metastasis. Dr. Khanna has over 100 publications in the area of cancer biology and therapy.
Lee Helman, MD
Dr. Helman is Director of the Osteosarcoma Institute and Adjunct Clinical Professor of Pediatrics, Cancer and Blood Disease Institute, CHLA, Keck School of Medicine, USC. Former Section Head of Basic and Translational Research within the Children's Center for Cancer and Blood Diseases and Director of the Cancer and Blood Diseases Research Program of the Saban Research Institute of Children's Hospital Los Angeles and Professor of Pediatrics in the Keck School of Medicine of USC. Dr. Helman has been studying the biology and caring for pediatric patients with sarcomas for over thirty years. He has also trained many investigators in the field of pediatric sarcomas. One current area of active research at Children’s Hospital Los Angeles focuses on using full genomic classification of osteosarcoma tumors to improve therapy, as well as testing novel therapeutic drugs and drug combinations in patients with osteosarcoma.
Dr. Helman received his medical degree from the University of Maryland School of Medicine magna cum laude in 1980 and was elected to Alpha Omega Alpha. He has served as scientific director for clinical research in the Center for Cancer Research at the NIH until 2016. He was elected to the American Society for Clinical Investigation and the American Association of Physicians and is a founding member and past president of the Connective Tissue Oncology Society. He is a past member of the Board of Governors of the Clinical Center at NIH. In addition to his many appointments with different organization, he has been appointed director of the Osteosarcoma Institute.
Scott Sauer, PhD
Head of Preclinical Discovery
Scott is a passionate and innovative scientist with extensive research expertise, as well as experience in biotech strategy & business development, alliance management and intellectual property. Scott’s multidisciplinary training in the fields of cancer biology, immunotherapy and organic chemistry provides a unique perspective to tackle difficult biological problems and unmet medical needs.
Prior to Vuja De, Scott joined SQZ Biotechnologies in 2016 where he worked as a researcher while managing the company’s intellectual property and academic collaborations. Scott received his postdoctoral training at Duke University from 2011-2016. His postdoctoral work was primarily in cancer biology focusing on mechanisms of therapeutic resistance and disease progression. During this time, Scott received numerous postdoctoral awards including his work on the interplay between cancer progression and environmental toxicants. Scott received his PhD at Duke University in organic chemistry in 2011 and a BS from the University of Maryland, Baltimore County (UMBC) in 2005.
George Sledge, MD - Medical Adviser
Chief of Oncology, Department of Medicine, Stanford University. Former president of the American Society for Clinical Oncology
Joseph Sparano, MD - Medical Adviser Professor of Medicine & Obstetrics, Gynecology, and Women's Health at the Albert Einstein College of Medicine, Associate Chairman for Clinical Research in the Department of Oncology at Montefiore Medical Center, and Associate Director for Clinical Research at the Albert Einstein Cancer Center, New York, NY
Kathy D. Miller, MD - Medical Adviser
Ballve-Lantero Professor, Associate Director for Clinical Research, IU Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN
Paul Wright, MD - Medical Adviser
Principal, AMWright Consulting; Experienced clinician, executive and adviser, Great Neck, NY
Steven Allen, MD - Medical Adviser
Professor of Medicine at the Zucker School of Medicine at Hofstra/Northwell, Associate Chief, Division of Hematology, Department of Medicine and Attending Physician, Division of Medical Oncology/Hematology at the Monter Cancer Center, Northwell Health Cancer Institute, Professor at the Karches Center for Oncology Research/Feinstein Institute for Medical Research.
Aykut Uren, MD - Cancer Recurrence Drug Discovery & Development
Professor, Department of Oncology, Department of Biochemistry and Molecular & Cellular Biology, Lombardi Comprehensive Cancer Center, Georgetown University
Dalit Barkan, Ph.D. - Cancer Recurrence Drug Discovery
Head, Laboratory of Tumor Dormancy and Metastasis, Department of Human Biology and Medical Sciences, Faculty of Natural Sciences, University of Haifa, Israel
Gil Ben Menachem, Ph.D. - Business Development and Strategy
Experienced biopharma executive. VP, BD at Kitov Pharma, formally Teva, Dexcel Pharma, Paramount Biosciences
Hynda K. Kleinman, Ph.D. - Scientific Affairs
Experienced research scientist, executive and industry adviser. Former Chief, Cell Biology Section, CDBRB, NIDCR, NIH
Jonathan Sleeman, Ph.D. - Cancer Recurrence Biology & Drug Discovery
Franz-Volhard Professor for Microvascular Biology and Pathobiology at the Medical Faculty Mannheim, University of Heidelberg
Lawrence N. Kwong, Ph.D. - Cancer Recurrence Biology & Drug Discovery
Assistant Professor of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center
Mike Ihnat, Ph.D. - Cancer Recurrence Drug Discovery
Associate Professor of Pharmacology, Department of Pharmaceutical Sciences, University of Oklahoma College of Pharmacy, Adjunct Associate Professor of Physiology, University of Oklahoma College of Medicine, Associate Member, Peggy and Charles Stephenson, Oklahoma Cancer Center, Experimental Therapeutics Program, University of Oklahoma College of Medicine, USA
Pui-Kai (Tom) Li, Ph.D. - Drug Discovery
Associate Professor, Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Ohio State University
Rafael Torgovicky, MD - Product Innovation, Business Development and Strategy
Experienced biopharma executive. Formally Novartis, Merck & Co, and Vice President, External Innovation – Oncology at Eli Lilly and Company
T.J. Sharpe – Patient Advocacy
Stage IV melanoma survivor, writer, advocate, and patient expert who began sharing his journey through cancer in the Patient #1 Blog on http://www.philly.com/patient1/.
Copyright © 2017 Vuja De Sciences lnc. - All Rights Reserved.